Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration <i>in vivo</i>

2 May 2005

Abstract excerpt

Neurofibrillary tangles composed of hyperphosphorylated, aggregated tau are a common pathological feature of tauopathies, including Alzheimer's disease. Abnormal phosphorylation of tau by kinases or phosphatases has been proposed as a pathogenic mechanism in tangle formation. To investigate whether kinase inhibition can reduce tauopathy and the degeneration associated with it in vivo, transgenic mice...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cholinesterase and Neurodegenerative Diseases
Share to Wnt/β-catenin signaling in development and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15867159
DOI: 10.1073/pnas.0500466102

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration <i>in vivo</i>PMID 15867159Read ↗

GSK‐3 in Neurodegenerative DiseasesSemantic proximity Read ↗

Functional Implications of Glycogen Synthase Kinase‐3‐Mediated Tau PhosphorylationSemantic proximity Read ↗

Tau kinase I overexpression induces dentate gyrus degeneration.Semantic proximity Read ↗

Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.Semantic proximity Read ↗

Inhibition of GSK-3 Ameliorates Aβ Pathology in an Adult-Onset Drosophila Model of Alzheimer's DiseaseSemantic proximity Read ↗

Selectively Silencing GSK-3 Isoforms Reduces Plaques and Tangles in Mouse Models of Alzheimer's DiseaseSemantic proximity Read ↗

Mechanisms and Therapeutic Implications of GSK-3 in Treating NeurodegenerationSemantic proximity Read ↗

A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.Semantic proximity Read ↗

Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease.Semantic proximity Read ↗

Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes.Semantic proximity Read ↗

Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells.Semantic proximity Read ↗

GSK-3β Contributes to Parkinsonian Dopaminergic Neuron Death: Evidence From Conditional Knockout Mice and TideglusibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.